1. Scrip
  2. >>Business

ArsenalBio Adds Genentech As A Partner While Embarking On Internal CAR-T Program

 
• By Jessica Merrill

The start-up will secure $70m from Genentech, after closing a series B financing, while it moves its first CAR-T program into the clinic for ovarian cancer later this year.

multi-pronged tree
ArsenalBio aims to growth through a multi-pronged business strategy • Source: Shutterstock

Just weeks after Arsenal Biosciences, Inc. announced the closing of a $220m series B financing, the company announced a partnership with Roche Holding AG's Genentech, Inc.  under which it will receive a $70m upfront payment.

The South San Francisco-based start-up is pursuing a multi-pronged business strategy to develop its own internal CAR-T therapies for solid tumors while also partnering

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

More from Business